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Summary 
 
Protein A (Spa) is a surface-associated protein of Staphylococcus aureus best known for 
its ability to bind to the Fc region of IgG. Spa also binds strongly to the Fab region of the 
immunoglobulins bearing VH3 heavy chains and to von Willebrand factor (vWF).  
Previous studies have suggested that the protein A-vWF interaction is important in S. 
aureus adherence to platelets under conditions of shear stress. We demonstrate that Spa 
expression is sufficient for adherence of bacteria to immobilized vWF under low fluid 
shear. The full-length recombinant Ig-binding region of protein A, Spa-EDABC, fused to 
glutathione-S-transferase (GST), bound recombinant vWF in a dose-dependent and 
saturable fashion with half-maximal binding of about 30 nM in immunosorbent assays.  
Full-length (FL)-Spa did not bind recombinant vWF A3 domain but displayed binding to 
recombinant vWF domains A1 and D'-D3 (half-maximal binding at 100 nM and 250 nM, 
respectively). Each recombinant Protein A Ig-binding domain bound to the A1 domain in 
a similar manner to the FL-Spa molecule (half-maximal binding 100 nM).  Amino acid 
substitutions were introduced in the GST-SpaD protein at sites known to be involved in 
IgG Fc or in VH3-Fab binding.  Mutants altered in residues that recognized IgG Fc but 
not those that recognized VH3 Fab had reduced binding to vWF A1 and D'-D3. This 
indicated that both vWF regions recognized a region on helices I and II that overlapped 
the IgG Fc binding site.  
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Introduction 
 
Staphylococcus aureus is a commensal of moist squamous epithelial surfaces, primarily 
in the anterior nares, where it permanently colonizes 20% of the population and  
transiently colonizes another 60% [1]. It can cause superficial skin infections such as 
abscesses and impetigo, and more serious invasive infections such as osteomyelitis, 
septic arthritis and endocarditis. Indeed, S. aureus is the leading cause of infective 
endocarditis where the bacterium can initiate infection of previously undamaged heart 
valves [2]. 
S. aureus has the ability to express a number of cell wall-anchored surface 
proteins that bind to plasma proteins or to components of the extracellular matrix. This 
facilitates evasion of immune responses, colonization of damaged tissue and adhesion to 
host cells and to platelets [3-5]. The interaction between S. aureus and platelets is a 
critical step in S. aureus-induced endocarditis. It has been demonstrated previously that 
the plasma proteins fibrinogen and fibronectin can act as bridges between bacterial cells 
and the platelet intergrin GPIIb/IIIa on resting platelets, through interactions with 
staphylococcal surface proteins clumping factor A and fibronectin binding proteins. [6-9]. 
In each case, antibodies specific to the surface protein are also required to form a bridge 
to the platelet FcγRIIa receptor. This can lead to infective vegetations in the vascular 
endothelium. 
Protein A (Spa) is a major surface protein of S. aureus. It comprises 4 or 5 
homologous repeat domains of 56-61 residues followed by a polymorphic variable repeat 
region Xr and a conserved region Xc, which includes a cell-wall attachment sequence 
(Fig. 1B) [10, 11]. Structural analysis of a single Spa domain revealed that it is composed 
of a 3 helical bundle. The solved structures of Spa domains in complex with IgG Fc and 
with a VH3-derived IgM Fab demonstrate how different parts of the Spa repeat are 
involved in the two interactions. Indeed, it is possible for a single Spa domain to bind 
each ligand simultaneously [12-14].  
Spa is known to bind human von Willebrand factor (vWF), a protein that is 
essential for haemostasis, with an affinity of 15 nM as measured by surface plasmon 
resonance using full length recombinant protein A and vWF that had been purified from 
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plasma. This interaction was shown to occur in the presence of physiological IgG 
concentrations [15]. Heritable defects in vWF result in von Willebrand’s disease, a 
common bleeding disorder, symptoms of which can mirror severe haemophilia. The main 
function of vWF is to capture platelets by binding to the platelet receptor GPIb-α and 
immobilise them at the site of damage to a blood vessel and to stimulate the formation of 
a blood clot. The vWF protein consists of four types of repeat domain A, B, C and D. 
Domains are arranged in the sequence D'-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK in the 
mature protein (Fig. 1A) (for review, see [16]). The crystal structure of the recombinant 
A1 domain in complex with platelet glycoprotein GpIb-α has been solved [17-19]. 
Binding of circulating vWF to the ligands such as collagen in exposed subendothelial 
matrix of damaged blood vessels under high shear-stress stimulates a conformational 
change which promotes immobilized vWF binding to GpIb-α on platelets [20-22]. 
Circulating platelets are captured and activated, stimulating the formation of a thrombus 
[23, 24].  
The ability of S. aureus to bind vWF could contribute to the adherence of the 
bacterium to platelets or to damaged blood vessels. By studying a Spa-deficient mutant of 
S. aureus it was shown that the Spa-vWF interaction is necessary for efficient recruitment 
of S. aureus by platelets under high shear stress in whole blood [25]. Also fluid-shear 
adhesion experiments suggested  that vWF  binding to Spa can promote adherence of 
circulating S. aureus cells to immobilised collagen [26]. In this study we set out to 
analyze the interaction between Spa and vWF. We demonstrate, using Lactococcus lactis 
as a surrogate host for protein expression, that Spa is sufficient for adherence of bacteria 
to immobilized vWF under low shear conditions. We used recombinant Spa and vWF 
truncates to identify and characterize the domain(s) in each protein that are involved in 
binding and refined the vWF binding domain in protein A by site-directed mutagenesis. 
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Results 
 
Perfusion studies 
 
 To determine whether expression of protein A on the cell surface is sufficient for 
adhesion of bacteria to immobilized vWF under flow, L. lactis or L. lactis Spa+ were 
perfused over glass slides coated with recombinant human vWF. Cells were perfused for 
300 seconds, and adherent bacteria visualized by video microscopy. Adherent bacteria 
were observed only in the case of the L. lactis expressing protein A.  Binding occurred at 
low shear rates (50 s-1) but not at high shear rates (Fig. 2A). Quantitative analysis was 
performed by counting adherent cells from at least three separate fields at 60 second time 
intervals (Fig. 2B). This supports previous work suggesting that Spa on the surface of S. 
aureus is necessary for efficient attachment of bacteria to a vWF-collagen complex at 
low shear rates [26] by demonstrating that it is sufficient for this process. 
Immobilised L. lactis or L. lactis Spa+ were tested for their ability to recruit 
platelets in whole blood under various conditions of shear. None of the shear rates tested 
(50 s-1 to 1500 s-1) supported platelet adhesion by L. lactis or L. lactis Spa+ (data not 
shown). 
 
Identification of regions within von Willebrand factor that bind to protein A 
 
 It was shown previously that vWF purified from human plasma bound to full length 
recombinant protein A with an apparent Kd of 15 nM measured by surface plasmon 
resonance [15]. Here ELISA-type binding assays were employed to study the interaction 
between recombinant protein A and recombinant vWF. Firstly, full-length (FL) 
recombinant vWF and the extracellular repeat region of Spa fused to GST (GST-
SpaEDABC) were used (see Fig. 1B). When FL-vWF was immobilized onto ELISA 
plates, binding of soluble GST-SpaEDABC occurred in a dose-dependent and saturable 
fashion with half-maximal binding at approximately 30 nM (Fig. 3A). Similar data were 
obtained when soluble FL-vWF was tested in binding experiments with immobilized 
GST-SpaEDABC (Fig. 3B). This showed that the Spa bound via its N-terminal EDABC 
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domains to vWF specifically and with high affinity, and that recombinant human vWF 
behaved in a similar fashion to plasma-derived protein used previously.     
In order to identify the binding site(s) for Spa in vWF, the D'-D3, A1 and A3 
truncates of vWF (Fig. 1A) were tested for their ability to bind to immobilized GST-
SpaEDABC. The A1 domain of vWF bound to GST-SpaEDABC dose-dependently and 
saturably with half-maximal binding at 100 nm. Binding was also detected for the vWF 
D'-D3 domain but with a lower affinity (half-maximal binding at 250 nm). In contrast, 
the A3 domain of vWF did not bind to GST-SpaEDABC (Fig. 4A).  This shows that vWF 
contains a high affinity Spa binding domain in domain A1 and a lower affinity site in 
domain D'-D3. To demonstrate specificity of these interactions, vWF A1 and D'-D3 were 
tested for binding to immobilized GST-SpaEDABC in the presence of increasing 
concentrations of soluble GST-SpaEDABC. The soluble Spa inhibited binding in a dose-
dependent and saturable manner, providing further evidence of the specificity of the 
interaction (Fig. 4B).  
 
Individual domains of protein A bind von Willebrand factor 
 
 Each of the homologous domains E, D, A, B and C of protein A can bind individually to 
the Fc region of IgG and to the Fab region of IgM that of the VH3 subclass [11, 34]. In 
order to investigate if each domain can bind to vWF, GST-SpaE, GST-SpaD, GST-SpaA, 
GST-SpaB and GST-SpaC fusions (see Fig. 1B) were tested for their ability to bind to the 
vWF A1 domain by Western ligand blotting.  When 250 ng of GST-Spa constructs were 
probed with 250 nm vWF A1, binding was detected for each of the Spa constructs except 
for GST-SpaE (Fig. 5A). Weak binding was detected only when larger amounts of GST-
SpaE were tested (Fig. 5B).   
Binding of Spa domains to vWF was also investigated with ELISA-type binding 
assays. Each GST-Spa truncate was immobilized and tested for its ability to bind soluble 
vWF A1 and D'-D3 proteins. The GST-Spa fusions bound to vWF A1 dose-dependently 
and saturably with similar affinity (half-maximal binding at approximately 100 nm) (Fig.  
5C). Each GST-Spa fusion also bound to the D'-D3 domain with similar affinities (not 
shown). It is noteworthy that GST-SpaE behaved in a similar fashion to the other GST-
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Spa constructs. The apparent lower affinity of the E domain for vWF A1 in ligand 
blotting could be explained by slower renaturation of the protein after transfer from the 
SDS-PAGE gel to the PVDF membrane. Alternatively, reduced binding may be due to 
the detrimental effect of blotting procedure on folding of the SpaE domain. It is also 
worth noting that the E domain of Spa has the greatest amino acid sequence differences 
from the other Spa domains.    
 
SpaD binding to vWF A1 is inhibited by IgG Fc regions but not a VH3-Fab 
 
 Hartleib et al., (2000) reported inhibition of the Spa-vWF interaction by IgG [15]. This 
suggests a possible shared binding region on Spa for IgG Fc and vWF. However, the 
large IgG molecule might have sterically blocked vWF binding. In addition, the pooled 
IgG used may have contained antibodies against Spa [15]. To overcome these potential 
problems, here the Fc fragment of IgG was used for binding and inhibition studies along 
with a recombinant VH3 heavy chain fragment JMSpa3-08, with a non-reactive VH4-
bearing IgM included as a control. Binding of Spa to Fc and VH3-derived 
immunoglobulin occurs through distinct binding regions within the Spa domain and is 
non-competitive, as demonstrated by the structures of complexes and by sandwich 
ELISA assays [12, 13]. Inhibition studies performed here revealed that the Fc fragment 
blocked vWF A1 binding in a dose-dependent and saturable manner while the VH3 heavy 
chain fragment had no effect (Fig. 6) which strongly suggests that vWF A1 binds to the 
same region of Spa as the Fc fragment of IgG.  
 
Amino acid substitutions of SpaD 
 
GST-fusion proteins of Spa domain D bearing substitutions in residues known to be 
involved in Fc or VH3-Fab binding [12, 35] were generated, to identify the residues on 
Spa involved in binding to vWF A1. The D domain of Spa was chosen because its crystal 
structure has been solved. A 58-residue variant (GST-SpaD58) of GST-SpaD, lacking the 
additional N-terminal residues unique to SpaD was also included in this study. A number 
of residues were substituted in order to investigate a role in vWF binding (Fig 7A).  The 
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substitutions generated were F5A, Q9A, Q10A, F13A, Y14A, L17A, N28A, I31A, K35A 
(Fc binding), G29A, F30A, S33A, D36A, D37A, Q40A E47A (VH3-Fab binding), Q32A 
(proposed to have a minor contact in both interactions), N21A and R27A (conserved 
residues in all Spa repeats but not involved in Fc or VH3-Fab binding).  Variants were 
tested for binding to IgG and vWF A1 by ELISA-type assay. GST-SpaD58 bound with a 
similar affinity to wild-type GST-SpaD to both ligands. The substitution of N21, which is 
not involved in Fc or VH3-Fab binding showed no reduction in vWF binding. Residues 
Q10, F13, Y14, L17, R27, N28, F30, I31 and K35 were shown to be important in vWF 
binding (Fig. 7B). When these residues were mapped on the solved structure of SpaD, 
they were seen to form a cluster between helices I and II. With the exceptions of R27 and 
F30, these residues coincide with those involved in IgG Fc binding (Fig. 7B, [35]. 
Interestingly, a similar binding profile was observed for GST-SpaD variants binding to 
the A1 and D'D3 domains (data not shown). In contrast, residues known to be involved in 
the VH3-Fab binding (G29, S33 and D36, D37, Q40, E47) did not demonstrate reduced 
vWF binding when substituted. 
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Discussion 
 
Protein A is one of a number of surface proteins expressed on the surface of S. aureus 
that is known to interact with plasma proteins. Several studies have demonstrated a role 
for protein A in staphylococcal virulence. Protein A-defective (Spa-) mutants have 
reduced virulence in murine models of septic arthritis, septicaemia and skin abscesses, 
most likely due to the anti-phagocytic effect of Spa binding IgG Fc [36, 37]. In a murine 
pneumonia model, Spa- mutants showed reduced virulence where the pro-inflammatory 
properties of Spa binding to TNFR-1 were strongly implicated [38]. Spa has been shown 
to trigger apoptosis of murine B cells that express antigen-receptors with VH3-Fab 
analogues, with greatest efficiency for marginal zone B cells that are involved in defence 
from blood borne infections. This likely contributes to immunosuppression during S. 
aureus infection [39]. 
Fluid-shear experiments in solution have suggested a function for Spa in 
promoting bacterial adherence to platelets in whole blood under very high shear rates 
(5000 s-1)[25], such as those found in stenotic vessels [23]. However, under 
physiologically relevant shear conditions we could not detect capture of platelets by 
immobilized bacteria. Spa can mediate adherence of staphylococci to immobilized 
collagen under flow  in the presence of vWF [26]. Also it has been shown that Spa can 
mediate adherence of S. aureus to vWF-coated surfaces in conditions of low shear [15]. 
Here, by expression of protein A on the surface of a surrogate bacterial host L. lactis in 
the absence of other surface proteins of S .aureus, we demonstrated that Spa is sufficient 
to support bacterial adherence to immobilized vWF under low shear conditions (50 s-1), 
representing normal venous shear rates [23]. This is in agreement with previous studies 
using S. aureus cells that indicated that Spa was necessary for efficient binding [15, 26].  
Perfusions of whole blood at low shear rates across immobilized S. aureus leads to 
platelet capture and thrombus formation that was shown to be triggered by clumping 
factor A (Kerrigan et al., unpublished data). To determine if protein A contributed to this 
process, immobilized L. lactis expressing Spa was investigated for its ability to recruit 
platelets. However, under all conditions of shear tested, no platelet adherence was 
observed, suggesting protein A is not involved in thrombus formation by S. aureus. It is 
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more likely that Spa promotes bacterial binding to immobilized vWF, either bound 
directly to exposed subendothelial tissue or to platelets that had been previously captured. 
This opens the possibility that vWF contributes to the recruitment of Spa-expressing 
bacteria into vWF-rich platelet thrombi.  
This study identifies two binding regions on vWF, domains, D'-D3 and A1, with 
half-maximal binding values of 250 nM and 100nM, respectively (Fig. 4B).  Specificity 
of the interactions is demonstrated by the ability of soluble Protein A to compete for 
binding to immobilized Spa (Fig. 4B). The D'-D3 region of vWF is involved in binding 
and stabilizing blood coagulation Factor VIII. The A1 domain contains the binding site 
for the platelet receptor, GpIb. Spa binds to the D'-D3 and A1 domains with estimated 
half-maximal binding values of  250 and 100 nM, respectively. vWF has estimated 
dissociation constants for coagulation factor VIII, which it binds through the D'-D3 
region, ranging from 200-400 pM [40, 41].  However, it is reported that only one vWF 
subunit in fifty binds Factor VIII [41]. Therefore, it is possible that D'-D3 provides a 
more available, lower affinity site for Spa on vWF. The availability of binding sites on 
vWF is probably also limited by its globular shape [42, 43]. The vWF A3 domain did not 
bind Spa (Fig. 4A). 
Each individual Protein A Ig-binding domain was tested for binding to vWF A1 
by ligand affinity blotting. Binding was initially detected for domains D, A, B and C, but 
not domain E (Fig. 5A). While there is high homology between Spa domains, there are 
some differences (Fig. 7A). Indeed, SpaE is the most heterologous Spa domain. An 
interaction was observed when increased amounts of Spa E were used (Fig. 5B). When 
single Spa domains were tested for binding to vWF A1 by solid phase binding, all 
individual domains bound with equal affinity (Fig. 5C), suggesting the reduced binding 
observed by SpaE by ligand blot may be an artifact of the protein refolding. 
To help identify the region on Spa domain D responsible for vWF binding, the Fc 
region of human IgG and recombinant VH3 heavy chain fragment JMSpa3-08 were tested 
for their ability to inhibit binding of Spa-D to vWF. The Fc fragment, but not the VH3-
Fab inhibited vWF A1 binding to Spa in a dose-dependent and saturable manner (Fig. 6). 
This suggested the binding site for vWF on Spa domain D lies in a similar region to that 
of the Fc binding site. Site-directed mutagenesis of residues on Spa domain D confirmed 
 11
that helices I and II contain the vWF binding site as well as that of Fc. However, the 
binding site is not identical as the substitution of R27A reduced binding to vWF A1, but 
not IgG (Fig 7B). This residue lies in helix II of Spa, and its side-chain points between 
helices I and II, consistent with the inhibition studies (Fig. 8). With the exception of F30, 
substitution of residues that are involved in binding VH3 Fab had no effect on binding to 
vWF A1 (Fig. 7B). This is consistent with the inability of recombinant VH3-Fab to inhibit 
binding of Spa to vWF A1 (Fig. 6). The observed reduction in binding of the F30A 
variant may be due to structural changes in the Spa protein because the side chain of F30 
contributes to the hydrophobic core of the protein A helical structure (see Fig. 8A). 
Indeed, an F30A substitution in Spa has previously been shown to have dramatically 
decreased structural stability, despite still maintaining its affinity for the Fc region of IgG 
[44-46]. This is not the case for vWF A1. Relative binding of the Spa substitutions to IgG 
(Fig. 7B) were in agreement with previous reports [35, 46].  
In conclusion, we have demonstrated a direct role for Spa in adherence to surfaces 
through its interaction with vWF under flow. Mutagenesis studies on Spa have defined 
the binding site on Spa for vWF as lying between helices I and II, the same region that is 
responsible for the Fc interaction. All five Spa domains are capable of binding vWF, 
which may reduce competition for binding sites by Fc and vWF. Indeed, vWF 
interactions occur in the presence of normal serum levels of IgG [15]. This region of Spa 
could be a potential therapeutic target; however, further studies to define the specific role 
in vivo of the interaction are required.   
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Materials and Methods 
 
Bacterial strains and growth conditions 
 
DNA cloning was performed in Escherichia coli XL1-Blue (Qiagen).  TOPP3 
(Stratagene) or M15(pREP4) (Qiagen) were used for expression of recombinant proteins. 
E. coli was routinely grown in L-broth at 37˚ C with shaking at 200 rpm. Ampicillin (100 
µg/mL) and kanamycin (50 µg/mL) were incorporated into the media where appropriate.  
 
DNA constructions 
 
Fragments of the region of spa encoding the extracellular immunoglobulin-binding 
domains were isolated and cloned as follows; plasmid pSPA7235 [27] containing  the 
entire coding region of the spa gene of Staphylococcus aureus 8325-4 was used as a 
template for amplification of the five- and single-domain repeats of spa. Oligonucleotides 
were designed to each individual domain to allow amplification of individual protein A 
repeats (Table 1). Cross reaction of primers due to high sequence homology of the 
repeats was overcome by digestion of the spa template with unique restriction 
endonucleases prior to single domain amplifications. Restriction sites were incorporated 
at the 5' ends of the primers to facilitate directional cloning. PCR amplification was 
carried out in a DNA thermal cycler (Techne) with Pfu DNA-polymerase (Stratagene). 
Reactions were carried out with a 1-min denaturation step at 94 °C, a 1-min annealing 
step at 55 °C, and elongation at 72 °C for 1-2 min depending on the length of the desired 
PCR product. This standard cycle was repeated 30 times followed by incubation at 72 °C 
for 10 min. PCR products were purified using the High Pure™ PCR product purification 
kit (Roche), digested with the appropriate restriction endonucleases (Roche) for 1 h at 37 
°C, and cloned into plasmid pGEX-KG, previously digested with these enzymes. This 
was then transformed into E. coli XL1-Blue, and positive transformants were sequenced. 
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Site-directed mutagenesis of a domain of spa 
 
Mutations were introduced into domain D of protein A using a PCR-based mutagenesis 
strategy. Briefly, overlapping oligonucleotides carrying the desired mutation were 
combined with standard flanking primers to yield two overlapping mutant products. 
These were combined and amplified using the flanking primers alone to yield the mutant 
fusion product. In some cases, mutations were introduced using the Quikchange® 
method, according to manufacturer’s instructions (Stratagene). The following amino acid 
substitutions were constructed: F5A, Q9A, Q10A, F13A, Y14A, L17A, N21A, R27A, 
N28A, G29A, F30A, I31A, Q32A, S33A, K35A, D36A, D37A, Q40A and E47A. A 
variant of Spa domain D lacking three additional codons unique to this domain was also 
created by PCR as previously described, generating a 58-residue variant [13]. 
Oligonucleotides used to introduce mutations are listed in Table 2. Amplimers were 
cloned directionally into pGEX-KG and expressed as described above. 
 
 
 
Induction and purification of recombinant proteins 
 
For expression of recombinant Spa truncates, pGEX-KG constructs were purified from E. 
coli XL1-Blue using the Wizard® plasmid purification kit (Promega) and transformed 
into E. coli TOPP3. Overnight cultures were inoculated into fresh medium and grown to 
an OD600 of 0.5. Isopropyl β-D-thiogalactopyranoside (IPTG) was added to a 
concentration of 1.5 mM and the culture was grown for a further 3 h. Cells were 
harvested by centrifugation at 7,000 rpm for 10 min in a Sorvall GS-3 rotor. The pellet 
was resuspended in PBS containing protease inhibitor (Roche), lysozyme (200 µg/mL) 
and DNase I (3 µg/mL). Cells were lysed by repeated passage through a French Pressure 
Cell. Cell debris was removed by centrifugation at 17,000 rpm for 30 min in a Sorvall 
SS-34 rotor and the supernatant was filtered through a 0.45 µm filter. Recombinant 
proteins expressed from pGEX-KG contained an N-terminal glutathione-S-transferase 
(GST) fusion of 26 kDa. The GST-fusion proteins were purified using a GSTrap™ 
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column (Amersham) and dialysed against phosphate-buffered saline (PBS). Recombinant 
five- and single-domain GST-fusion proteins had approximate Mws of 59 kDa and 32 
kDa, respectively.  
Recombinant VH3-Fab was produced in E. coli XL1-Blue from pComb3::JMSpA3-08 as 
described previously [28].  Murine VH4 IgM was produced as described elsewhere [29]. 
Recombinant full-length (FL) vWF and truncates D'-D3, A1, and A3 were cloned 
and expressed as described previously, from baby hamster kidney cells, Pichia pastoris 
and E. coli, respectively [18, 30, 31]. Recombinant vWF A1 domain was also produced 
in E. coli M15 cells harbouring plasmid pREP4 (Qiagen) from plasmid pQE30-vWF-A1 
as described previously [17, 32]. All vWF truncates contained an N-terminal histidine 
tag.  
 
Protein analysis and Western ligand blotting assays 
 
Recombinant proteins were analyzed by SDS-PAGE using gels containing 4.5-12.5% 
acrylamide. Gels were stained using Coomassie™ Brilliant Blue (Amersham) or by silver 
staining [33]. In some cases, proteins were transferred electrophoretically to 
polyvinylidene difluoride (PVDF) Western blotting membranes (Roche) by the wet 
system (Bio-Rad) in Tris-HCl (0.02 M), glycine (0.15 M), and methanol (20 % v/v). 
Membranes were incubated for 15 h at 4 °C in 5 % blocking reagent (Marvel milk 
powder). Membranes were washed and incubated with gentle agitation with vWF as 
previously described [15]. F(ab’)2 were isolated from polyclonal anti-vWF-HRP (Dako) 
by pepsin digestion (Pierce) for detection of FL-vWF. vWF truncates were detected using 
HisProbe-HRP (Pierce). Membranes were developed using LumiGLO chemiluminescent 
substrate (New England Biolabs) according to the manufacturer's instructions. 
 
Preparation of flow chamber slides 
 
 Purified vWf was used at a concentration of 100µg/ml. A 500µl solution was applied to 
glass slides (75 x 25 mm) and allowed to attach for 2hrs at room temperature in a 
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humidity chamber. Slides were washed 3 times in PBS buffer to remove any unbound 
protein. Finally, the slides were blocked with 1% BSA for a further 1 hour at 37ºC.  
 
Videomicoscopy 
 
 Overnight cultures of bacteria were washed twice in PBS and resuspended to an OD600 
of 1. Next, cells were perfused over immobilized vWF at various shear rates. A syringe 
pump (Harvard Biosciences, MA, USA) was used to aspirate bacteria through the flow 
chamber. Bacterial adhesion was visualized using phase contrast microscopy (63X LD-
Achroplan objective) through the flow chamber (GlycoTech, Rockville, MD, US) 
mounted on a Zeiss Axiovert-200 epi-fluorescence microscope (Carl Zeiss, Welwyn 
Garden City, UK). Images were captured every second up to 300s by a liquid chilled 
Quantix-57 CCD camera (Photometrics Ltd, Tuscon, AZ, USA). Bacterial adhesion was 
analysed using MetaMorph (Universal Imaging Corp., Downingtown, PA, USA).  
 
Recombinant protein binding assay 
 
Microtitre plates (Starstedt) were coated with Spa or vWF in carbonate buffer overnight 
at 4 °C. Wells were washed three times with Tween 20 (0.05 % v/v) in PBS and blocked 
at 37 °C with 3 % (w/v) bovine serum albumin (BSA) in PBS for 2 h at 37 °C. Wells were 
again washed and varying concentrations of appropriate ligand in 3 % BSA were added. 
Plates were incubated for 1 h at 37˚C. Unbound protein was removed by washing. Bound 
vWF was detected as before. Bound Spa was detected by HRP-chicken anti-GST 
antibody (Gallus Immunotech). After washing, 100 µl of a chromogenic substrate 
solution (1 mg/ml tetramethylbenzidine and 0.006 % H2O2 in 0.05 M phosphate citrate 
buffer pH 5.0) was added, and plates were developed for 10 min. The reaction was 
stopped by the addition of 2 M H2SO4 (50 µl/well), and plates were read at 450 nm. Data 
from ELISA-type assays was graphed and analysed using GraphPad Prism version 4.00 
for Windows, GraphPad Software, San Diego, California, USA.  
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Inhibition studies 
 
ELISA plates were coated and blocked as before. Wells were incubated with mixtures 
containing increasing concentrations of inhibitor and a standard concentration of ligand 
corresponding to its half-maximal binding to the coated protein as determined by ELISA-
type binding assays. Inhibition was performed using Spa and vWF truncates, and also the 
Fc portion of human IgG (Jackson Labs, Inc., USA) and a VH3-Fab fragment, produced 
in E. coli from plasmid pComb3::JMSpA3-08 as previously described [28].  Wells were 
washed and bound protein was detected as before. Percentage inhibition was calculated 
from the percentage of bound protein detected in the absence of inhibitor.  
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Table 1. Oligonucleotides for single spa domain constructs.  
Restriction sites are indicated in boldface type. 
Name Sequence (5’-3’) 
Fw_spaE 
Rv_spaE 
Fw_spaD           
Fw_spaA            
Rv_spaD/A        
Fw_spaB            
Fw_spaC           
Rv_spaB/C        
CCGGAATTCATGCTGCGCAACACGATGAAG 
CCGCCATGGTTATTTTGGTGCTTGAGAGTCA 
CCGGAATTCAAGCTGATGCGCAACAAAATAAC 
CCGGAATTCAAGCTGATAACAATTTCAACAAAG 
CCGCCATGGTTATTTCGGTGCTTGAGATTCG 
CCGGAATTCAAGCGGATAACAAATTCAACAAAG 
CCGGAATTCAAGCTGACAACAAATTCAACAAAG 
CCGCCATGGTTATTTTGGTGCTTGAGCATCAT 
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Table 2. Oligonucleotides used for spaD variants.  
Reverse primers for all variants is the reverse complement of forward primer. restriction sites are 
indicated in boldface type and underlined bases indicate a changed codon. 
Name Forward Primer (5’-3’) 
Fw_spaD58 
F5A 
Q9A 
Q10A 
F13A 
Y14A 
L17A 
N21A 
R27A 
N28A 
G29A 
F30A 
I31A 
Q32A 
S33A 
K35A 
D36A 
D37A 
Q40A 
E47A 
CCGGAATTCAAGCTGATAATAACTTCAACAAAG 
GCAACAAAATAACGCGAACAAAGATC 
CTTCAACAAAGATGCACAAAGCGCC 
CAACAAAGATCAAGCAAGCGCCTTC 
CAAAGCGCCGCGTATGAAATC 
GCGCCTTCGCGGAAATCTTG 
CTATGAAATCGCGAACATGCC 
GAACATGCCTGCGTTAAACGAAG 
GAAGCGCAAGCTAACGGCTTC 
CCAACGTGCGGGCTTCATTC 
GCAACGTAACGCGTTCATTCA 
GTAACGGCGCGATTCAAAGTC 
GTAACGGCTTCGCGCAAAGTC 
GGCTTCATTGCGAGTCTTAAAG 
GCTTCATTCAAGCGCTTAAAGAC 
GTCTTGCGGACGACCCAAG 
GTCTTAAAGCGGACCCAAGCC 
CTTAAAGACGCGCCAAGCC 
GACGACCCAAGCGCAAGCACTAACG 
CGTTTTAGGTGCAGCTAAAAAATTAAACG 
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Figure Legends 
 
 
Fig. 1. Recombinant protein constructs. A,  von Willebrand Factor (vWF). vWF is composed 
of four types of repeat domain (A, B, C, D). Full-length vWF and regions D′-D3, A1 and A3, 
denoted by horizontal lines, were created as recombinant protein with N-terminal His tags. B, 
staphylococcal Protein A. Recombinant N-terminal GST fusions to the entire extracellular repeat 
region of Spa (GST-SpaEDABC) and single domains (GST-SpaE, GST-SpaD, GST-SpaA, GST-
SpaB, GST-SpaC) were constructed, denoted by horizontal lines. 
 
Fig. 2. Perfusion of L. lactis expressing Spa over vWF-coated slides. L. lactis or L. lactis 
expressing Spa were perfused over glass slides covered with full-length vWF (100 µg/ml). Live 
imaging of adherent cells by videomicroscopy was performed as described in “Experimental 
Procedures”. A, images of L. lactis Spa+ after 0 and 300 seconds of perfusion over vWF. B, 
Adherent bacterial cells were counted from three independent fields of view at 60 second 
intervals for both L. lactis and L. lactis Spa+. 
 
Fig. 3. Interaction of full-length (FL-) vWF to GST-SpaEDABC. A, Microtitre wells were 
coated with vWF (10µg/mL) and incubated with increasing concentrations of GST-SpaEDABC. 
HRP-conjugated chicken anti-GST antibody was used to detect bound GST-SpaEDABC. In the 
reverse assay, binding of soluble vWF to immobilised SpaEDABC (10 µg/mL) was detected 
using HRP-anti-6xHis monoclonal antibody (B). Values are the means ± standard deviation of 
triplicate wells. The experiment was performed three times in triplicate with similar results. 
 
 
Fig. 4. Binding of GST-SpaEDABC to recombinant vWF truncates. A, microtitre plates were 
coated overnight with GST-SpaEDABC (10 µg/mL) and incubated with increasing 
concentrations of vWF D'D3, A1 or A3. Bound vWF constructs were detected with HRP-anti-His 
monoclonal antibody. Half-maximal binding for vWF A1 and D′D3 truncates was observed at 
100 nm and 250 nm, respectively. B, vWF A1 (100 nm) or D′D3 (250 nm) were incubated with 
increasing concentrations of Spa and tested for binding to immobilised Spa. Percentage binding 
relative to vWF binding in the absence of soluble Spa was calculated. Values are the means ± 
standard deviation of triplicate wells. The experiment was performed three times in triplicate with 
similar results.  
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Fig. 5. Interaction of single GST-Spa domains with vWF A1. A, individual GST-Spa domains 
(250 ng) were separated by SDS-PAGE, immobilised on PVDF membrane and assayed for vWF 
A1 binding by ligand affinity blotting. B, increasing concentrations of domains GST-SpaE and 
GST-SpaD (500 ng, 1µg, 2µg) were assayed by for vWF A1 binding by ligand affinity blotting. 
C, interaction of GST-SpaE, GST-SpaD, GST-SpaA, GST-SpaB and GST-SpaC domains to 
soluble vWF A1 by ELISA-type assay.  Values represent the mean of triplicate determinations. 
Binding curve represents average of all data values from GST-Spa truncates. Experiments were 
performed three times. 
 
Fig. 6. Inhibition of Spa binding to vWF A1 by Fc and VH3-Fab. 96-well plates coated with 
GST-SpaD (10µg/mL) were incubated with a mixture of vWF A1 (100 nM) and various 
concentrations of Fcγ or VH3-Fab. A VH4-bearing IgM, which does not bind Spa, was also 
included. Bound vWF was monitored using a HRP-conjugated anti-Hisx6 antibody. Percentage 
inhibition was calculated relative to vWF bound in the absence of inhibitor. The experiment was 
performed three times with similar results. 
 
Fig. 7. Effect on ligand binding of SpaD substitutions. A, alignment of the five domains of 
protein A based on SpaD. Conserved residues are denoted by an asterisk (*), conserved 
substitutions in residues by a colon (:) and semi-conserved residues by a stop (.). Residues 
substituted or deleted by site-directed mutagenesis are highlighted grey. B, ELISA plates were 
coated with GST-SpaD variants (10µg/ml) followed by incubation with rabbit IgG or vWF A1 at  
concentrations corresponding to half-maximal binding to wild-type GST-SpaD as previously 
determined by ELISA. Adherent protein was detected as described in “Experimental Procedures”.   
Experiments were performed in triplicate on three separate occasions. Figures represent the mean 
± SD from a typical result obtained. 
 
Fig. 8. The Binding site for vWF A1 on SpaD. Ribbon diagram of SpaD from above (A) and 
the side (B) based its solved structure (PDB ID: 1DEE), with residues shown to be important in 
vWF A1 binding highlighted in spacefill. Amino acids which show a similar affect in IgG Fc 
binding are coloured red, while only affecting the vWF A1 interaction are in blue. The binding 
site for both vWF A1 and IgG Fc is confined to the helix1-2 interface. Variant F30A shows a 
decrease in vWF A1 binding, but is known to be essential for the structural integrity of the Spa 
three-helix bundle.   
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure 8 
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